Personalized Cancer Treatment
đź©ş A New Era in Personalized Cancer Treatment
Cancer therapies have come a long way, but one major challenge remains: predicting whether a drug will actually work for a specific patient. Doron Gerber and his team have developed OncoFlow, a microfluidic platform that tests how an individual’s tumor cells respond to different treatments—before those treatments are prescribed.
Rather than relying solely on genetic profiling, this approach provides a real-time, functional readout of drug sensitivity, helping oncologists make faster, more informed decisions while sparing patients from ineffective treatments and unnecessary side effects.
🔬 Why this is a game-changer:
✔️ Provides personalized treatment guidance based on actual tumor behavior       ✔️ Avoids the trial-and-error of cancer therapy
✔️ Accelerates the move toward truly functional precision medicine
This technology could significantly reshape how cancer treatments are tailored, ensuring that the right drug reaches the right patient at the right time. Exciting work by Doron Gerber and his team—looking forward to seeing its impact in the clinic!
Â
